Low Dose of Lenvatinib Treatment for Patients of Radioiodine-Refractory Differentiated Thyroid Carcinoma - A Real-World Experience.

He-Jiun JiangYen-Hsiang ChangYen-Hao ChenFeng-Yu ChiangPei-Wen WangPi-Jung Hsiao

Published in: Cancer management and research (2021)

Assessing treatment intensity, safety and efficacy, low-dose lenvatinib treatment was well tolerated by RRDTC patients and displayed acceptable drug efficacy and outcomes.

Keyphrases

low dose
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
type diabetes
emergency department
metabolic syndrome
adipose tissue
high intensity
insulin resistance